유전체학 데이터 분석 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 기술별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Genomics Data Analysis Market Size, Share & Trends Analysis Report By Service (Variant Calling & Annotation, Gene Expression Analysis), By Technology (NGS, Microarray, PCR), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,845,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,332,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,305,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

유전체학 데이터 분석 시장 요약

세계의 유전체학 데이터 분석 시장 규모는 2024년에 56억 8,000만 달러로 평가되었고, 2033년까지 204억 9,000만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지의 CAGR은 15.40%를 나타낼 것으로 전망됩니다. 이 성장 궤도는 차세대 시퀀싱(NGS) 채택 가속화, 정밀의료 이용 확대, 클라우드 기반 바이오인포매틱스 플랫폼에 대한 수요 증가를 반영합니다.

공공 부문과 민간 부문에 의한 투자 증가와 인공지능(AI) 및 머신러닝(ML)의 유전체 프로세스에의 통합은 시장 성장을 더욱 지원할 것으로 기대됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 부수 시장 전망
• 시장 동향과 전망
• 시장 역학
  • 시장 성장 촉진요인의 영향 분석
  • 시장 성장 억제요인의 영향 분석
• 비즈니스 환경 분석
  • PESTLE 분석
  • Porter's Five Forces 분석

제4장 서비스 비즈니스 분석

• 서비스 부문 대시보드
• 세계의 유전체학 데이터 분석 시장 : 서비스, 변동 분석
• 세계의 유전체학 데이터 분석 시장 규모와 동향 분석(서비스별, 2021-2033년)
• 데이터 전처리 및 품질 관리
• 변이 탐지 및 주석 부착
• 유전자 발현 분석
• 데이터 분석 및 보고
• 기타

제5장 기술 비즈니스 분석

• 기술 부문 대시보드
• 세계의 유전체학 데이터 분석 시장 : 기술, 변동 분석
• 세계의 유전체학 데이터 분석 시장 규모와 동향 분석(기술별, 2021-2033년)
• 차세대 시퀀싱(NGS)
• 마이크로어레이
• PCR
• CRISPR 기반 분석
• 기타

제6장 용도 비즈니스 분석

• 용도 부문 대시보드
• 세계의 유전체학 데이터 분석 시장 : 용도, 변동 분석
• 세계의 유전체학 데이터 분석 시장 규모와 동향 분석(용도별, 2021-2033년)
• 진단
• 신약 개발
• 기타

제7장 최종 용도 비즈니스 분석

• 최종 용도 부문 대시보드
• 세계의 유전체학 데이터 분석 시장 : 최종 용도, 변동 분석
• 세계의 유전체학 데이터 분석 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
• 학술 및 연구 기관
• 제약 및 바이오테크놀러지 기업
• 병원과 연구소
• 기타

제8장 유전체학 데이터 분석 시장 : 서비스, 기술, 용도, 최종 용도별 지역 추정 및 동향 분석

• 지역 대시보드
• 시장 규모와 예측 및 동향 분석(2021-2033년)
• 북미
  • 북미의 유전체학 데이터 분석 시장(2021-2033년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 유전체학 데이터 분석 시장(2021-2033년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 유전체학 데이터 분석 시장(2021-2033년)
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 라틴아메리카의 유전체학 데이터 분석 시장(2021-2033년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • MEA의 유전체학 데이터 분석 시장(2021-2033년)
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 기업 분류
• 전략 매핑
• 기업시장 포지셔닝 분석(2024년)
• 기업 프로파일/상장 기업
  • Illumina, Inc.
  • QIAGEN
  • CD Genomics
  • CellCarta
  • Charles River Laboratories
  • BGI
  • Fios Genomics
  • Eurofins Genomics
  • Basepair
  • Golden Helix

KTH

영문 목차

영문목차

Genomics Data Analysis Market Summary

The global genomics data analysis market size was estimated at USD 5.68 billion in 2024 and is projected to reach USD 20.49 billion by 2033, growing at a CAGR of 15.40% from 2025 to 2033. This growth trajectory reflects the accelerating adoption of next-generation sequencing (NGS), the expanding use of precision medicine, and the rising demand for cloud-based bioinformatics platforms.

More public and private sector investments and incorporating artificial intelligence (AI) and machine learning (ML) into genomic processes will help support additional market growth.

Global Genomics Data Analysis Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global genomics data analysis market based on service, technology, application, end use, and region:

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Data Preprocessing and Quality Control
• Variant Calling and Annotation
• Gene Expression Analysis
• Data Interpretation and Reporting
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Next-Generation Sequencing (NGS)
• Microarray
• PCR
• CRISPR-based Analysis
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostics
• Drug Discovery & Development
  • Oncology
  • Neurology
  • Infectious Diseases
  • Others
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals & Labs
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Service
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Impact Analysis
    • 3.3.1.1. AI & machine learning integration
    • 3.3.1.2. Explosion of Genomic Data
  • 3.3.2. Market Restraint Impact Analysis
    • 3.3.2.1. High cost of genomic analysis infrastructure
    • 3.3.2.2. Data privacy & security concerns
• 3.4. Business Environment Analysis
  • 3.4.1. PESTLE Analysis
  • 3.4.2. PORTER'S Five Forces Analysis

Chapter 4. Service Business Analysis

• 4.1. Service Segment Dashboard
• 4.2. Global Genomics Data Analysis Market Service, Movement Analysis
• 4.3. Global Genomics Data Analysis Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 4.4. Data Preprocessing and Quality Control
  • 4.4.1. Global data preprocessing and quality control market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Variant Calling and Annotation
  • 4.5.1. Global variant calling and annotation market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Gene Expression Analysis
  • 4.6.1. Global gene expression analysis market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Data Interpretation and Reporting
  • 4.7.1. Global data interpretation and reporting market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Global others media market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Global Genomics Data Analysis Market Technology, Movement Analysis
• 5.3. Global Genomics Data Analysis Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 5.4. Next-Generation Sequencing (NGS)
  • 5.4.1. Global next-generation sequencing (NGS) market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Microarray
  • 5.5.1. Global microarray market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. PCR
  • 5.6.1. Global PCR market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. CRISPR-based Analysis
  • 5.7.1. Global CRISPR-based analysis market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Genomics Data Analysis Market Application, Movement Analysis
• 6.3. Global Genomics Data Analysis Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Diagnostics
  • 6.4.1. Global diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Drug Discovery & Development
  • 6.5.1. Global drug discovery & development market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.1. Oncology
      • 6.5.1.1.1. Global oncology market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.2. Neurology
      • 6.5.1.2.1. Global neurology market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.3. Infectious Diseases
      • 6.5.1.3.1. Global infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.5.1.4. Others
      • 6.5.1.4.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global Genomics Data Analysis Market End Use, Movement Analysis
• 7.3. Global Genomics Data Analysis Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Academic & Research Institutes
  • 7.4.1. Global academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Pharmaceutical & Biotechnology Companies
  • 7.5.1. Global pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Hospitals & Labs
  • 7.6.1. Global hospitals & labs market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Genomics Data Analysis Market: Regional Estimates and Trend Analysis, by Service, Technology, Application, & End Use

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 8.3. North America
  • 8.3.1. North America genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. U.S. genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Canada genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Mexico genomics data analysis market, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. UK genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Germany genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. France genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Italy genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Spain genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Denmark genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Sweden genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Target Disease Prevalence
    • 8.4.9.3. Competitive Scenario
    • 8.4.9.4. Regulatory Framework
    • 8.4.9.5. Norway genomics data analysis market, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Japan genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. China genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. India genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Competitive Scenario
    • 8.5.5.4. Regulatory Framework
    • 8.5.5.5. Australia genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Competitive Scenario
    • 8.5.6.4. Regulatory Framework
    • 8.5.6.5. Thailand genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Competitive Scenario
    • 8.5.7.4. Regulatory Framework
    • 8.5.7.5. South Korea genomics data analysis market, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Brazil genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Argentina genomics data analysis market, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Competitive Scenario
    • 8.7.2.4. Regulatory Framework
    • 8.7.2.5. South Africa genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Competitive Scenario
    • 8.7.3.4. Regulatory Framework
    • 8.7.3.5. Saudi Arabia genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Target Disease Prevalence
    • 8.7.4.3. Competitive Scenario
    • 8.7.4.4. Regulatory Framework
    • 8.7.4.5. UAE genomics data analysis market, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Target Disease Prevalence
    • 8.7.5.3. Competitive Scenario
    • 8.7.5.4. Regulatory Framework
    • 8.7.5.5. Kuwait genomics data analysis market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Illumina, Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Service Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. QIAGEN
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Service Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. CD Genomics
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Service Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. CellCarta
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Service Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Charles River Laboratories
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Service Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. BGI
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Service Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Fios Genomics
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Service Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Eurofins Genomics
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Service Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Basepair
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Service Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Golden Helix
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Service Benchmarking
    • 9.4.10.4. Strategic Initiatives

관련자료